Brokers Offer Predictions for Edesa Biotech Q3 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Brookline Capital Markets issued their Q3 2026 earnings estimates for shares of Edesa Biotech in a research report issued on Monday, June 29th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.49) per share for the quarter. Brookline Capital Markets has a “Strong-Buy” rating on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.57) per share. Brookline Capital Markets also issued estimates for Edesa Biotech’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($2.11) EPS and FY2028 earnings at ($2.51) EPS.

Several other research analysts have also issued reports on the company. Wall Street Zen raised Edesa Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Edesa Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Edesa Biotech Stock Performance

Shares of NASDAQ EDSA opened at $7.75 on Thursday. The firm has a 50 day moving average price of $9.51 and a two-hundred day moving average price of $5.38. The stock has a market cap of $68.90 million, a P/E ratio of -5.78 and a beta of 1.03. Edesa Biotech has a 52-week low of $0.72 and a 52-week high of $20.32.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.25).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP bought a new position in shares of Edesa Biotech in the third quarter valued at approximately $36,000. State Street Corp bought a new stake in Edesa Biotech during the 4th quarter worth approximately $27,000. Diadema Partners LP purchased a new stake in Edesa Biotech in the 4th quarter worth approximately $77,000. DRW Securities LLC purchased a new stake in Edesa Biotech in the 4th quarter worth approximately $191,000. Finally, Perceptive Advisors LLC bought a new position in Edesa Biotech in the 1st quarter valued at $2,946,000. Hedge funds and other institutional investors own 5.50% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.